🔊🎧 🎙️ What's New in PsO TX: My Real World Experience with Bimekizumab PART 2 🔊🎧 🎙️🩺🔍 Age-defying Dr.Marni Wiseman journeys with us through 22 years in #dermatology, spilling the secrets of revolutionary treatments and today's #psoriasis patient journeys. 🔊🎧 From the evolution of 1st gen biologic therapy to the latest data around Bimekizumab and it's role, we dive into a fresh discussion about Dr.Wiseman's secret sauce when it comes to treating plaque #psoriasis. 🔊🎧Hear about her initial approach to biologic naïve patients to determine suitability for biologic therapy. Don't let PART 2 be skin deep; dive right in! 🎙️🩺🔍 In PART 2 we explore: We deep dive into the real world experience with Dr. Wiseman who brings clarity to the use of Bimekizumab and other molecules in treating moderate to severe plaque psoriasis The convenience of Bimekizumab's dosing schedule, its tolerability, and its significant impact on patient-reported outcomes and quality of life. Dr. Wiseman provides a comprehensive view on managing treatment accessibilityand coverage in different Canadian provinces, and nuances in coverage and criteria for accessing Bimekizumab. Dr. Wiseman's approach to baseline workups for patients, emphasizing the importance of screening for comorbidities like psoriatic arthritis and her anticipations for Bimekizumab's expanding indications. She also sheds light on new developments in treating Hidradenitis Suppurativa (HS) with Bimekizumab, based on recent clinical trial data. Join us for a masterclass in understanding and managing psoriasis with Dr. Marni Wiseman on the podcast. 🎙️Spoiler alert: Not all IL-17 inhibitors are created equal! And if you're itching (pun intended) to learn about that one Bimekizumab side effect everyone's talking about and the real world experience, tune in! #DermTalks #Derm #MedicineMeetsManagement #BehindTheStethoscope #HealthcareDeepDive #PatientCareFirst #PracticePerfect #SkinAndSystems #DoctorDiaries #ClinicCheckup #HealthcareHacks #OptimizedOutcomes #DermDeepDive Only on the Skin and Joints Podcast ! ▶️Episode supported by UCB. ABOUT Dr.Marni Wiseman MD FRCPC Dr. Marni Wiseman began her Dermatology practice in Winnipeg, Manitoba in 2001. In addition to her teaching responsibilities as an Associate Professor and Section Head of Dermatology in the Faculty of Medicine at the University of Manitoba, Dr. Wiseman is the Medical Director of SKiNWISE DERMATOLOGY where she is involved in a general dermatology practice. Dr. Wiseman’s areas of interest include psoriasis, atopic dermatitis, hidradenitis suppurativa, acne, and aesthetic dermatology. She actively participates in clinical trials through Wiseman Dermatology Research, where she has participated in over a hundred clinical trials. Dr. Wiseman is a frequent supervisor and mentor for medical students and residents. She has extensively published in areas of inflammatory skin disease, photodermatosis, and cutaneous malignancy. Her community commitments are extensive and include involvement with the Canadian Dermatology Association as Provincial Director of the National Sun Awareness Program. She is an editor of the Journal of Cutaneous Medicine and Surgery, and was the chair of the Skin Cancer Disease Site Group at CancerCare Manitoba for 15 years. Dr. Wiseman does regular outreach skin cancer screening clinics in rural locations of Manitoba, has been featured in many news stories, and regularly presents at meetings and congresses nationally and internationally.
🔊🎧 🎙️ What's New in PsO TX: My Real World Experience with Bimekizumab PART 2 🔊🎧
🎙️🩺🔍 Age-defying Dr.Marni Wiseman journeys with us through 22 years in #dermatology, spilling the secrets of revolutionary treatments and today's #psoriasis patient journeys.
🔊🎧 From the evolution of 1st gen biologic therapy to the latest data around Bimekizumab and it's role, we dive into a fresh discussion about Dr.Wiseman's secret sauce when it comes to treating plaque #psoriasis.
🔊🎧Hear about her initial approach to biologic naïve patients to determine suitability for biologic therapy.
Don't let PART 2 be skin deep; dive right in! 🎙️🩺🔍
In PART 2 we explore:
Join us for a masterclass in understanding and managing psoriasis with Dr. Marni Wiseman on the podcast.
🎙️Spoiler alert: Not all IL-17 inhibitors are created equal! And if you're itching (pun intended) to learn about that one Bimekizumab side effect everyone's talking about and the real world experience, tune in!
#DermTalks #Derm #MedicineMeetsManagement #BehindTheStethoscope #HealthcareDeepDive #PatientCareFirst #PracticePerfect #SkinAndSystems #DoctorDiaries #ClinicCheckup #HealthcareHacks #OptimizedOutcomes #DermDeepDive
Only on the Skin and Joints Podcast !
▶️Episode supported by UCB.
ABOUT Dr.Marni Wiseman MD FRCPC
Dr. Marni Wiseman began her Dermatology practice in Winnipeg, Manitoba in 2001. In addition to her teaching responsibilities as an Associate Professor and Section Head of Dermatology in the Faculty of Medicine at the University of Manitoba, Dr. Wiseman is the Medical Director of SKiNWISE DERMATOLOGY where she is involved in a general dermatology practice.
Dr. Wiseman’s areas of interest include psoriasis, atopic dermatitis, hidradenitis suppurativa, acne, and aesthetic dermatology. She actively participates in clinical trials through Wiseman Dermatology Research, where she has participated in over a hundred clinical trials. Dr. Wiseman is a frequent supervisor and mentor for medical students and residents. She has extensively published in areas of inflammatory skin disease, photodermatosis, and cutaneous malignancy.
Her community commitments are extensive and include involvement with the Canadian Dermatology Association as Provincial Director of the National Sun Awareness Program. She is an editor of the Journal of Cutaneous Medicine and Surgery, and was the chair of the Skin Cancer Disease Site Group at CancerCare Manitoba for 15 years. Dr. Wiseman does regular outreach skin cancer screening clinics in rural locations of Manitoba, has been featured in many news stories, and regularly presents at meetings and congresses nationally and internationally.